Charting a new course at the FDA
By Marcia Angell | Monday, April 6, 2009 | The Boston Globe
“…On March 14, President Obama nominated Margaret Hamburg to become commissioner of the FDA and appointed Joshua Sharfstein, a longtime critic of the pharmaceutical industry, as her principal deputy. Sharfstein, who does not need Senate approval, took over the agency as acting commissioner last week, pending Hamburg’s confirmation. His appointment gives real hope that the FDA will stop kowtowing to the big drug companies. For too long the agency has behaved as though its job is to speed brand-name drugs to market, not to ensure that they are safe and effective. But while new leadership is crucial, more needs to be done….”…BS
This entry was posted on Monday, April 6th, 2009 at 5:10 AM and filed under Health, History, Politics. Follow comments here with the RSS 2.0 feed. Skip to the end and leave a response. Trackbacks are closed.
